Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(16):1191-1193; doi:10.1093/jnci/94.16.1191
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Baldwin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baldwin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 16, 1191-1193, August 21, 2002
© 2002 Oxford University Press

NEWS

FDA Evaluating Oxaliplatin for Advanced Colorectal Cancer Treatment

Joyce Baldwin

The first 10% of the full text of this article appears below.

Three years ago, oxaliplatin (Eloxatine) was in the headlines as the first potential breakthrough in 30 years in the treatment of advanced metastatic colorectal cancer. Results from clinical trials suggested that the addition of oxaliplatin to standard chemotherapy regimens was associated with an improvement in median progression-free survival exceeding 8 months and in median survival to nearly 16 months.

Despite these results, in April 2000 the U.S. Food and Drug Administration declined to approve the use of oxaliplatin in combination with the standard chemotherapy regimen of 5-fluorouracil and leucovorin (5-FU/LV) as a first-line therapy for advanced and metastatic colorectal cancer because the data available at that time from multi-institutional phase III trials failed to show that the drug combination had a survival advantage . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
D. Santini, B. Vincenzi, A. La Cesa, M. Casale, F. Salvinelli, and G. Tonini
Recurrent Episodes of Involuntary Masticatory Spasms Induced by Continuous Infusion of Oxaliplatin
J Natl Cancer Inst, October 15, 2003; 95(20): 1555 - 1556.
[Full Text] [PDF]